Enterome, a Paris, France-based a stratified medicine company developing biomarkers for chronic and challenging medical conditions relating to abnormalities of bacterial composition of the human intestine (metabolic and bowel diseases), has held a €5m first closing of a Series A funding round.
This funding, which follows a previous €1.5m seed round, will enable Enterome to validate its proprietary biomarkers, translate them into high value medical diagnostics and offer these tests as Laboratory Developed Test services in the US and EU.
Enteromes’ two lead projects are in Non-Alcoholic Fatty Liver Disease (NAFLD) and in Inflammatory Bowel Diseases (IBD).
Led by CEO Pierre Belichard, Enterome has initially developed its technology at the INRA laboratory of Dusko Ehrlich at Jouy-en-Josas, France.
The company presently employs 6 people.